Potent, ATP-competitive VEGFR, PDGFRβ
and KIT inhibitor (Ki
values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ
and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
Soluble to 25 mM in DMSO
Store at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Molecular basis for sunitinib efficacy and future clinical development
Faivre et al.
Nat.Rev.Drug Discov., 2007;6:734
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel et al.
Clin.Cancer Res., 2003;9:327
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell et al.
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
The citations listed below are publications that use Tocris products. Selected citations for Sunitinib malate include:
Showing Results 1 - 2 of 2